Predicting recurrence risk of Leigh syndrome using prenatal mtDNA heteroplasmy assessment
Mitochondrion · 2026-09 · 90 · 102165
DOI: 10.1016/j.mito.2026.102165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mitochondrion, 2026-09. Verfasst von Maria Shishimorova und 16 weiteren Autor:innen. Beteiligte Einrichtung: Center for Embryonic Cell and Gene Therapy, Oregon Health & Science University, 3303 South Bond Avenue, Portland, OR 97239, USA. Hauptthemen laut MEDLINE: Leigh Disease, DNA, Mitochondrial, Heteroplasmy, Prenatal Diagnosis. Die Arbeit nennt 17 Literaturangaben. Gefördert von: Oregon Health & Science University, Burroughs Wellcome Fund, Medical University of South Carolina.
Abstract (Originalsprache)
Predicting recurrence risk for mitochondrial DNA (mtDNA) disorders is challenging because heteroplasmy levels can shift during development. We examined whether prenatal heteroplasmy measurements predict postnatal outcomes for the pathogenic m.13513G > A variant associated with Leigh syndrome. In a longitudinal family-based study involving three naturally conceived pregnancies, mtDNA heteroplasmy was assessed by chorionic villus sampling at 10-12 weeks of gestation and, when available, amniocentesis at 16 weeks, with follow-up in neonatal and postnatal tissues. Prenatal heteroplasmy levels below ∼30% were associated with unaffected outcomes, whereas an affected sibling exhibited near-homoplasmic variant loads in critical organs. These findings suggest prenatal heteroplasmy assessment may inform recurrence risk for the mtDNA m.13513G > A disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Embryonic Cell and Gene Therapy, Oregon Health & Science University, 3303 South Bond Avenue, Portland, OR 97239, USA.
- Center for Embryonic Cell and Gene Therapy, Oregon Health & Science University, 3303 South Bond Avenue, Portland, OR 97239, USA; Current address: Center for Reproductive Medicine, Department of Obstetrics & Gynecology,…
- Department of Biomedical Science, College of Life Science, CHA Global Research Institute, CHA University, Seongnam 13488, South Korea.
- Center for Embryonic Cell and Gene Therapy, Oregon Health & Science University, 3303 South Bond Avenue, Portland, OR 97239, USA; Division of Reproductive Endocrinology & Infertility, Department of Obstetrics & Gynecolog…
- Norton Children's Hospital, 231 E Chestnut St, Louisville, KY 40202, USA.
- Department of Obstetrics & Gynecology, Division of Maternal Fetal Medicine, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425, USA.
Förderung
- Oregon Health & Science University
- Burroughs Wellcome Fund
- Medical University of South Carolina
Zitieren
APA
Shishimorova, M., Ma, H., Koski, A., Dyken, C. V., Gutierrez, N. M., Frana, D., Li, Y., Eyberg, D., Tevkin, S., Hayama, T., Kang, E., Amato, P., Havlin, K., Goodier, C., Newman, R., Shields, S., & Mitalipov, S. (2026). Predicting recurrence risk of Leigh syndrome using prenatal mtDNA heteroplasmy assessment. Mitochondrion, 90, 102165. https://doi.org/10.1016/j.mito.2026.102165
Vancouver
Shishimorova M, Ma H, Koski A, Dyken CV, Gutierrez NM, Frana D, et al. Predicting recurrence risk of Leigh syndrome using prenatal mtDNA heteroplasmy assessment. Mitochondrion. 2026;90:102165. doi:10.1016/j.mito.2026.102165
BibTeX
@article{Shishimorova2026,
author = {Shishimorova, Maria and Ma, Hong and Koski, Amy and Dyken, Crystal Van and Gutierrez, Nuria Marti and Frana, Daniel and Li, Ying and Eyberg, Daniel and Tevkin, Sergei and Hayama, Tomonari and Kang, Eunju and Amato, Paula and Havlin, Kevin and Goodier, Christopher and Newman, Roger and Shields, Sally and Mitalipov, Shoukhrat},
title = {Predicting recurrence risk of Leigh syndrome using prenatal mtDNA heteroplasmy assessment},
journal = {Mitochondrion},
year = {2026},
volume = {90},
pages = {102165},
doi = {10.1016/j.mito.2026.102165}
}
EUVIMED